复星医药(02196.HK) 宣布,用于治疗高甘油三酯血症(HTG)的肝靶向siRNA小干扰核酸创新药FXR0906注射液,于近日在中国境内完成I期临床首例参与者给药。FXR0906是一款肝靶向的siRNA小干扰核酸创新药,通过RNA干扰技术精准沉默APOC3基因表达,降低血清甘油三酯水平,从而实现对高甘油三酯血症的治疗。FXR0906由复星医药集团许可引进,并享有该药品于中国内地及港澳地区研究、...
Source Link复星医药(02196.HK) 宣布,用于治疗高甘油三酯血症(HTG)的肝靶向siRNA小干扰核酸创新药FXR0906注射液,于近日在中国境内完成I期临床首例参与者给药。FXR0906是一款肝靶向的siRNA小干扰核酸创新药,通过RNA干扰技术精准沉默APOC3基因表达,降低血清甘油三酯水平,从而实现对高甘油三酯血症的治疗。FXR0906由复星医药集团许可引进,并享有该药品于中国内地及港澳地区研究、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.